InVivo Therapeutics Announces Oral Platform Presentation at 2016 Congress of Neurological Surgeons Annual Meeting
September 14 2016 - 8:00AM
Business Wire
InVivo Therapeutics Holdings Corp. (NVIV) today
announced that Nicholas Theodore, M.D., Director of the John
Hopkins Neurosurgical Spine Center, will be giving an oral platform
presentation titled “High AIS Grade Conversion Rate Following
Neuro-Spinal Scaffold Implantation in Acute Thoracic Complete AIS A
Spinal Cord Injury (SCI): Potential Mechanisms” at the 2016
Congress of Neurological Surgeons (CNS) Annual Meeting to be held
September 24-28, 2016 in San Diego, CA. The presentation will be
made on Tuesday, September 27, during the section on Neurotrauma
and Critical Care.
Dr. Theodore said, “It has been encouraging to watch the INSPIRE
study results unfold. We have amassed a wealth of knowledge and I
look forward to sharing key insights with the neurosurgical
community.”
In addition, Robert Heary, M.D., Director of the Spine Center at
Rutgers New Jersey Medical School, will give a poster presentation
titled “MR Neuroimaging Does Not Accurately Identify
Intraparenchymal Cavities in the Spinal Cord Following AIS A
Thoracic Spinal Cord Injuries.” The company also will engage the
neurosurgical community through a steering committee meeting and an
exhibitor booth.
“We look forward to interacting with and growing the network of
neurosurgeons involved with our work and sharing our latest
findings with the neurosurgical community at this prominent
conference,” Mark Perrin, Chief Executive Officer and Chairman,
said.
About the Neuro-Spinal Scaffold™ Implant
Following acute spinal cord injury, surgical implantation of the
biodegradable Neuro-Spinal Scaffold within the decompressed and
debrided injury epicenter is intended to support appositional
healing, thereby reducing post-traumatic cavity formation, sparing
white matter, and allowing neural regeneration across the healed
wound epicenter. The Neuro-Spinal Scaffold, an investigational
device, has received a Humanitarian Use Device (HUD) designation
and currently is being evaluated in the INSPIRE pivotal probable
benefit study for the treatment of patients with complete (AIS A)
traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and
clinical-stage biomaterials and biotechnology company with a focus
on treatment of spinal cord injuries. The company was founded in
2005 with proprietary technology co-invented by Robert Langer,
Sc.D., Professor at Massachusetts Institute of Technology, and
Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital
and who now is affiliated with Massachusetts General Hospital. In
2011, the company earned the David S. Apple Award from the American
Spinal Injury Association for its outstanding contribution to
spinal cord injury medicine. In 2015, the company’s investigational
Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine
Device Award. The publicly-traded company is headquartered in
Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160914005153/en/
InVivo TherapeuticsBrian Luque, 617-863-5535Investor
Relationsbluque@invivotherapeutics.com
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024